Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study

[1]  B. Grunau,et al.  The Relationship Between Anti-Spike SARS-CoV-2 Antibody Levels and Risk of Breakthrough COVID-19 Among Fully Vaccinated Adults , 2022, The Journal of infectious diseases.

[2]  David A. Jolliffe,et al.  Correlation Between Postvaccination Anti-Spike Antibody Titers and Protection Against Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Population-Based Longitudinal Study , 2022, The Journal of infectious diseases.

[3]  G. Kochs,et al.  Optimized intramuscular immunization with VSV-vectored spike protein triggers a superior immune response to SARS-CoV-2 , 2022, NPJ vaccines.

[4]  H. van Bakel,et al.  Protection Associated with Previous SARS-CoV-2 Infection in Nicaragua , 2022, The New England journal of medicine.

[5]  Y. Kreiss,et al.  COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022 , 2022, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[6]  E. Moga,et al.  The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection , 2022, Frontiers in Immunology.

[7]  Gheyath K Nasrallah,et al.  Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections , 2022, The New England journal of medicine.

[8]  T. Gonen,et al.  Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose , 2022, Nature Immunology.

[9]  M. Nussenzweig,et al.  Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost , 2022, Nature.

[10]  M. Ma,et al.  Delta infection following vaccination elicits potent neutralizing immunity against the SARS-CoV-2 Omicron , 2022, The Journal of infectious diseases.

[11]  D. Harats,et al.  Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron , 2022, The New England journal of medicine.

[12]  C. Balotta,et al.  Durability of Humoral Responses after the Second Dose of mRNA BNT162b2 Vaccine in Residents of a Long Term Care Facility , 2022, Vaccines.

[13]  A. Gingras,et al.  Longitudinal Assessment of SARS-CoV-2-Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multicytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity , 2022, bioRxiv.

[14]  Arthur Young.  T cells in SARS-CoV-2 infection and vaccination , 2022, Therapeutic advances in vaccines and immunotherapy.

[15]  L. Bekker,et al.  Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa , 2021, The New England journal of medicine.

[16]  Y. Kreiss,et al.  Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection , 2021, medRxiv.

[17]  Z. Ademi,et al.  Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis , 2021, BMJ.

[18]  H. Zar,et al.  Towards a population-based threshold of protection for COVID-19 vaccines , 2021, Vaccine.

[19]  G. Rahav,et al.  Early Immunogenicity and safety of the third dose of BNT162b2 mRNA Covid-19 vaccine among adults older than 60 years; real world experience. , 2021, The Journal of infectious diseases.

[20]  Z. Ademi,et al.  Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis , 2021, BMJ.

[21]  Michael I. Mandel,et al.  Waning Immunity after the BNT162b2 Vaccine in Israel , 2021, The New England journal of medicine.

[22]  Y. Kreiss,et al.  Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months , 2021, The New England journal of medicine.

[23]  C. Cao,et al.  COVID-19 Vaccines: Current Conditions and Future Prospects , 2021, Biology.

[24]  Michael I. Mandel,et al.  Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel , 2021, The New England journal of medicine.

[25]  M. Lipsitch,et al.  Covid-19 Breakthrough Infections in Vaccinated Health Care Workers , 2021, The New England journal of medicine.

[26]  A. Huppert,et al.  BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers , 2021, The Lancet Respiratory Medicine.

[27]  O. Mor,et al.  Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[28]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[29]  D. Swerdlow,et al.  Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data , 2021, The Lancet.

[30]  Y. Kreiss,et al.  Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients , 2021, The Lancet.

[31]  D. Lauffenburger,et al.  Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[32]  J. Mascola,et al.  An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.

[33]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[34]  Douglas G Altman,et al.  Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines , 2009, BMC medical research methodology.